What is iOmx?
iOmx Therapeutics, based in Martinsried, Germany, is a biopharmaceutical company dedicated to pioneering first-in-class cancer immuno-therapeutics. The company's core focus lies in targeting novel immune checkpoints that are frequently hijacked by cancer cells, aiming to unlock new avenues for treating various forms of cancer. By developing innovative therapies, iOmx seeks to address unmet medical needs in oncology and improve patient outcomes through advanced biological insights and drug development.
How much funding has iOmx raised?
iOmx has raised a total of $120M across 2 funding rounds:
Series A
$44.6M
Series B
$75.4M
Series A (2016): $44.6M with participation from Merck Ventures, MPM Capital, Sofinnova Partners, and Wellington Partners
Series B (2021): $75.4M led by Sofinnova Partners, Athos Group, Wellington Partners, Merck Ventures, and MIG Capital
Key Investors in iOmx
Merck Ventures
Merck Ventures is the corporate venture capital arm of Merck, focused on investing in innovative technologies with the potential to impact core business areas. They actively engage with portfolio companies to drive commercial success, with a strong emphasis on early-stage investments and company creation.
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specializing in life sciences, with a focus on healthcare and sustainability. They act as hands-on company builders, partnering with entrepreneurs to develop transformative innovations from seed to later stages.
Wellington Partners
Wellington Partners is a prominent European venture capital firm investing in early- and growth-stage life science companies. They support entrepreneurs in transforming innovative ideas into successful businesses, with a focus on therapeutics, medical devices, and digital health.
What's next for iOmx?
The recent major strategic investment signals a pivotal phase for iOmx Therapeutics, likely enabling the company to accelerate its research and development pipeline, advance its lead candidates into clinical trials, and potentially expand its therapeutic targets. This infusion of capital will be crucial for scaling operations, bolstering its scientific team, and navigating the complex regulatory landscape. The company's focus on novel immune checkpoints positions it to potentially disrupt the immuno-oncology market, making its future developments closely watched by the biopharmaceutical industry and investors alike.
See full iOmx company page
